Neurocrine Biosciences
NBIX
218 hedge funds and large institutions have $4.7B invested in Neurocrine Biosciences in 2015 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 92 increasing their positions, 72 reducing their positions, and 23 closing their positions.
52% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 23
43% more capital invested
Capital invested by funds: $3.29B → $4.7B (+$1.41B)
29% more call options, than puts
Call options by funds: $36.2M | Put options by funds: $28.1M
28% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 72
5% more funds holding
Funds holding: 207 → 218 (+11)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$43.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$33.4M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$21.2M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$20.2M |
| 5 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$19.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$66.1M |
| 2 |
PA
Perceptive Advisors
New York
|
-$22.7M |
| 3 |
Jennison Associates
New York
|
-$19.2M |
| 4 |
TCP
Tourbillon Capital Partners
New York
|
-$18M |
| 5 |
Millennium Management
New York
|
-$13.6M |
NBIX Hedge Fund Activity: Q4 2015 in Review
218 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q4 2015, worth a combined $4.7B — up 43% from $3.29B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new NBIX positions and 23 closed out — a net gain of 12 holders — while 92 added to existing stakes and 72 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $43.9M. The largest seller was OrbiMed, cutting an estimated $66.1M.
- 218 institutional investors held Neurocrine Biosciences (NBIX) as of Q4 2015, up from 207 in Q3 2015.
- Funds reported $4.7B of Neurocrine Biosciences stock for Q4 2015, up 43% quarter-over-quarter.
- 35 funds opened new Neurocrine Biosciences positions in Q4 2015 and 23 closed out, a net change of +12 holders.
- The largest Neurocrine Biosciences buyer in Q4 2015 was T. Rowe Price Associates, an estimated $43.9M added.
- The largest Neurocrine Biosciences seller in Q4 2015 was OrbiMed, an estimated $66.1M sold.
Based on aggregated 13F filings for Q4 2015.